Drug Trial Radar · NCT07557121
Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
35
Planned (sponsor's estimate)
Start
Jul 1, 2026
Primary completion
Jun 30, 2027
Study completion Aug 23, 2027
Sponsor
- Lead sponsor
- AiViva BioPharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- ClinDatrix, Inc.
- First posted
- Apr 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to evaluate whether AIV007 provides benefits to patients with neovascular age-related macular degeneration in improving vision and that it has an acceptable safety profile. Participants will receive either a periocular injection of AIV007 or intravitreal injection of Eylea (control arm) to the study eye and return to the clinic monthly for safety and efficacy observations and/or continued treatment. Participants may receive additional treatment(s) if they meet specified criteria.
Conditions
- Neovascular (Wet) Age-Related Macular Degeneration
Interventions
AIV007Drug
6 mg or 8 mg dose
EYLEA® (aflibercept) Injection 2 mg (0.05mL)Biological
Eylea 2 mg, marketed product
Primary outcomes
What the sponsor says the trial is designed to measure.
- Best-corrected Visual AcuityTime frame: Month 6
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Macula and Vitreous Center
Torrance, California · Recruiting
Valley Retina Institute, P.A.
McAllen, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.